SEC Tracker
Get the app

Neumora Therapeutics NMRA

Neumora Therapeutics faces Nasdaq delisting risk

Nasdaq bid price notice, cure by Apr 26, 2027, Item 3.01 Listing standards notice

Form
8-K
Filed
Importance
Major
  1. Received Nasdaq notice of noncompliance with $1.00 minimum bid price
  2. 180-day compliance period ends April 26, 2027
  3. May transfer to Nasdaq Capital Market if unable to meet bid price requirement

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Neumora Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The company has 180 days, until April 26, 2027, to regain compliance.
  2. To do so, the closing bid price of its common stock must meet or exceed $1.00 per share for ten consecutive business days during this period.
  3. If Neumora does not regain compliance by April 26, 2027, it may apply to transfer to The Nasdaq Capital Market.
  4. This would require meeting other listing standards, including market value of publicly held shares, and paying an application fee.
  5. The company would also need to notify Nasdaq of its intent to cure the bid price deficiency.
  6. If Neumora fails to comply with the minimum bid price requirement, Nasdaq may delist its stock.
  7. The company could appeal, but there is no guarantee of approval.

7 of 8 claims matched the filing text.

Not found in the filing text

  • Neumora Therapeutics, Inc. filed a Form 8-K on October 30, 2026, reporting that it received a notice from Nasdaq indicating it was not in compliance with the $1.00 minimum bid price requirement for continued listing.

From the filing

Item 3.01

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 26, 2026, Neumora Therapeutics, Inc. (the "Company") received written notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until April 26, 2027, to regain compliance with the minimum bid price requirement1. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period2.

If the Company is not in compliance by April 26, 2027, the Company may be eligible for additional time to regain compliance.3 3To qualify, the Company would be required to submit an application to transfer to The Nasdaq Capital Market3, which would require the Company to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement.4 4In addition, the Company would be required to pay an application fee to Nasdaq4 and notify Nasdaq of its intent to cure the minimum bid price deficiency5.

If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting6. The Company would then be entitled to appeal Nasdaq's determination, but there can be no assurance that Nasdaq would grant the Company's request for continued listing7.

The Company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance with the minimum bid price requirement, including effecting a

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Lifevantage LFVN public float $64M, Dec 31, 2025
  2. Veru VERU public float $64M, Mar 31, 2025, over 18 months old
  3. Medicinova MNOV public float $62M, Jun 30, 2025
  4. Whitehawk Therapeutics WHWK public float $65M, Jun 30, 2025
  5. PDS Biotechnology PDSB public float $60M, Jun 30, 2025